Loading...
Please wait, while we are loading the content...
Longitudinally Profiling Neutralizing Antibody Response to SARS
| Content Provider | CiteSeerX |
|---|---|
| Author | Pseudotypes, Coronavirus Temperton, Nigel J. Chan, Paul K. Simmons, Graham Zambon, Maria C. Tedder, Richard S. Takeuchi, Yasuhiro Weiss, Robin A. |
| Abstract | The severe acute respiratory syndrome–associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replicationcompetent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines. The coronavirus that causes severe acute respiratory syndrome (SARS-CoV) is a new human pathogen for which a vaccine may be urgently required should a new outbreak occur. Studying the magnitude and longevity of the neutralizing antibody response during natural infection will help establish correlates of protection to be generated by immunization. Humoral immunoglobulin (Ig) G, IgM, and IgA responses to SARS-CoV have been studied extensively (1–7). However, studies of neutralizing antibody responses during natural infection have been limited (8,9), partially because neutralization assays must be performed at biosafety level 3 or higher. |
| File Format | |
| Access Restriction | Open |
| Subject Keyword | Antibody Response Natural Infection Severe Acute Respiratory Syndrome Pseudotype Assay Major Target Neutralization Titer Live Sars Virus Recovered Patient Replicationcompetent Sars-cov Iga Response Confirmed Sars Patient Sars-cov Neutralizing Antibody Useful Tool Retroviral Sars-cov Pseudotypes New Outbreak Occur Long-lasting Immunity Neutralization Assay Biosafety Level Humoral Immunoglobulin Preclinical Evaluation Spike Protein Candidate Vaccine New Human Pathogen Strain Oc43 Vitro Microneutralization Assay Sequential Serum Sample Human Serum |
| Content Type | Text |
